PA
LMAT icon

PharVision Advisers’s LeMaitre Vascular LMAT Stock Holding History

PharVision Advisers’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,053
Closed -$355K – 868
2025
Q3 		$355K Buy
+4,053
New +$362K 0.2% 136

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PharVision Advisers's LMAT Position: Q4 2025 in Review

PharVision Advisers sold out of LeMaitre Vascular (LMAT) in Q4 2025, closing a stake of 4,053 shares — an estimated $355K sold.

PharVision Advisers first reported a position in LMAT in Q3 2025 and held it in 1 quarter. The position peaked at $355K in Q3 2025. 297 funds tracked by Wall St. Rank hold LMAT as of Q4 2025.

  • PharVision Advisers reported no remaining LeMaitre Vascular position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 4,053 LeMaitre Vascular shares in Q4 2025, an estimated $355K.
  • PharVision Advisers first reported a position in LeMaitre Vascular in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's LeMaitre Vascular position peaked at $355K in Q3 2025.
  • 297 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.